Sign in
TerminatedPhase 2

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Key facts

Who runs it
Vertex Pharmaceuticals Incorporated
Where
Chapel Hill, Falls Church, Gainesville, Hannibal, Houston, Iowa City, Kansas City, New York, Orlando, and Salt Lake City, United StatesSee the 10 sitesAlso in 3 other countries, 3 sites
Status
Terminated
Phase
Phase 2
People taking part
14 people enrolled
Started
23 Feb 2023
Ended
19 Aug 2024
Type of study
Interventional, 2 groups
Treatments tested
  • VX-864
Record updated
8 September 2025
Why it stopped
Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participants must have a PiZZ genotype confirmed at screening
  • Plasma AAT levels indicating severe deficiency at screening

Who cannot take part

  • Solid organ, or hematological transplantation or is currently on a transplant list
  • History of use of gene therapy or Ribonucleic acid interference (RNAi) therapy at any time previously
  • Participants for whom discontinuation of augmentation therapy is not considered to be in their best interest, based on the clinical judgement of the treating physician; Other protocol defined Inclusion/Exclusion criteria may apply
  • History of a medical condition that could negatively impact the ability to complete the study

Where in United States

Also in 3 other countries, 3 sites

  • Marsico Clinical Research Center at UNC Pulmonary ClinicChapel Hill, United States
  • Inova Fairfax Medical CampusFalls Church, United States
  • University of FloridaGainesville, United States
  • Hannibal Regional Healthcare SystemHannibal, United States
  • Renovatio ClinicalHouston, United States
  • The University of Iowa Hospitals and Clinics: Adult Pulmonary ClinicIowa City, United States
  • University of Kansas Medical CenterKansas City, United States
  • Columbia University Irving Medical CenterNew York, United States
  • Central Florida Pulmonary Group, P.A.Orlando, United States
  • University Of Utah HealthSalt Lake City, United States

About the trial

What the trial wants to find out

The purpose of this study evaluates the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.

The 2 groups in the trial

  • Group ATreatment being tested

    Participants received VX-864 every 12 hours (q12h) for 48 weeks or until study drug dosing was terminated.

    Treatment: VX-864

  • Group BTreatment being tested

    Participants undergo a liver biopsy before receiving VX-864 q12h for 48 weeks or until study drug dosing was terminated, and undergo a second liver biopsy at either Week 24 or Week 48.

    Treatment: VX-864

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
Record updated
8 September 2025